GFM
AARD

GF Fund Management’s Aardvark Therapeutics AARD Stock Holding History

GF Fund Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.82K Buy
483
+56
+13% +$581 ﹤0.01% 622
2025
Q4 		$5.6K Buy
+427
New +$5.33K ﹤0.01% 620

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GF Fund Management's AARD Position: Q1 2026 in Review

GF Fund Management increased its Aardvark Therapeutics (AARD) stake by 13% in Q1 2026, buying an estimated $581 and bringing the position to 483 shares worth $1.82K. The position accounts for ﹤0.01% of the portfolio, ranked #622.

GF Fund Management first reported a position in AARD in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.6K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • GF Fund Management held 483 shares of Aardvark Therapeutics worth $1.82K as of Q1 2026.
  • GF Fund Management bought 56 Aardvark Therapeutics shares in Q1 2026, an estimated $581.
  • Aardvark Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #622 holding.
  • GF Fund Management first reported a position in Aardvark Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • GF Fund Management's Aardvark Therapeutics position peaked at $5.6K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.